A Phase IV, Randomized, Double-Blind, Placebo-Controlled Exploratory Study of Omalizumab for Treatment of Idiopathic Angioedema in Patients Who Remain Symptomatic Despite Current Therapy

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY（2022）

引用 2|浏览1

暂无评分

摘要

gov URL:https://clinicaltrials.gov/ct2/show/NCT02966314?term=omalizumab&cond=Angioedema&draw=2&rank=1.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要